Inhibitory effects of sildenafil on small intestinal motility and myoelectrical activity in dogs

Sildenafil normalizes bowel transit in preclinical models of constipation

Guanylyl cyclase-C (GC-C) agonists increase cGMP levels in the intestinal epithelium to promote secretion. This process underlies the utility of exogenous GC-C agonists such as linaclotide for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Because GC-C agonists have limited use in pediatric patients, there is a need for alternative cGMP-elevating agents that are effective in the intestine. The present study aimed to determine whether the PDE-5 inhibitor sildenafil has similar effects as linaclotide on preclinical models of constipation. Oral administration of sildenafil caused increased cGMP levels in mouse intestinal epithelium demonstrating that blocking cGMP-breakdown is an alternative approach to increase cGMP in the gut. Both linaclotide and sildenafil reduced proliferation and increased differentiation in colon mucosa, indicating common target pathways. The homeostatic effects of cGMP required gut turnover since maximal effects were observed after 3 days of treatment. Neither linaclotide nor sildenafil treatment affected intestinal transit or water content of fecal pellets in healthy mice. To test the effectiveness of cGMP elevation in a functional motility disorder model, mice were treated with dextran sulfate sodium (DSS) to induce colitis and were allowed to recover for several weeks. The recovered animals exhibited slower transit, but increased fecal water content. An acute dose of sildenafil was able to normalize transit and fecal water content in the DSS-recovery animal model, and also in loperamide-induced constipation. The higher fecal water content in the recovered animals was due to a compromised epithelial barrier, which was normalized by sildenafil treatment. Taken together our results show that sildenafil can have similar effects as linaclotide on the intestine, and may have therapeutic benefit to patients with CIC, IBS-C, and post-infectious IBS.

Inhibitory effects of sildenafil on gastric motility and gastric slow waves in dogs

The aim of this study was to investigate the effects of sildenafil on gastric motility and gastric slow waves in dogs. The study was performed in healthy dogs and composed of three experiments. The first experiment was designed to study the effects of sildenafil on gastric emptying and gastric slow waves. The second experiment was used to investigate the effects of sildenafil on gastric tone. The third experiment was used to study the effects of sildenafil on postprandial antral contractions. (i) Sildenafil did not alter gastric emptying of liquid. (ii) Sildenafil had no effects on dominant frequency and percentage of normal gastric slow waves. The dominant power of gastric slow waves was, however, significantly reduced with sildenafil (P < 0.02). (iii) Fasting gastric volume with sildenafil was significantly higher than that at baseline (P < 0.0005) or in the control session (P < 0.002). However, the postprandial gastric volume was not altered with sildenafil. (iv) Sildenafil inhibited gastric antral motility. The contraction index was 338.5 +/- 39.99 at baseline and 122.5 +/- 20.3 after the injection of sildenafil (P = 0.003). Sildenafil inhibits fundic tone and antral motility but does not seem to delay gastric emptying of liquid in dogs. The amplitude but not the frequency or regularity of the gastric slow wave is inhibited by sildenafil.